Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Rapport Therapeutics (RAPP) · oqro.io/stocks/RAPP · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
5 days before resultsTraded Oct 23 · filed the same day
Since the trade +0.8% · S&P 500 −0.7% · to Nov 13
A Rapport Therapeutics director paid $98K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in over a year.
6 days before resultsTraded Oct 22 · filed the same day
Since the trade −1.4% · S&P 500 −1.3% · to Nov 13
A Rapport Therapeutics director paid $974K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in 13 months.
6 days before resultsTraded Oct 22 · filed the same day
Since the trade −1.4% · S&P 500 −1.3% · to Nov 13
A Rapport Therapeutics director paid $100K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in 13 months.
6 days before resultsTraded Oct 22 · filed the same day
Since the trade −1.4% · S&P 500 −1.3% · to Nov 13
A Rapport Therapeutics director paid $100K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in over a year.
7 days before resultsTraded Oct 21 · filed the same day
Since the trade +4.3% · S&P 500 −2.4% · to Nov 13
The CFO of Rapport Therapeutics paid $144K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in 19 months.
Their first buy on recordTraded Sep 12, 2025 · filed 3 days later
A Rapport Therapeutics director paid $499K out of pocket for Rapport Therapeutics shares. 2 other people at Rapport Therapeutics bought some too, in the same month.
A Rapport Therapeutics director paid $79K out of pocket for Rapport Therapeutics shares. 2 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in 6 months.
11 open-market purchases and 8 open-market sales by insiders of RAPP between Feb 8, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Oct 30, 2026. The data provider lists the next release for Mar 8, 2027; that date may change.
PurchaseSale30 days before a release30 days after
Trades in the 30 days around each of the last earnings releases
James Healy, Director, Oct 28, 2026, about $146K. Bought 2 days before the company's next earnings release on 2026-10-30Form 4
James Healy, Director, Oct 28, 2026, about $79K. Bought 2 days before the company's next earnings release on 2026-10-30Form 4
James Healy, Director, Oct 28, 2026, about $134K. Bought 2 days before the company's next earnings release on 2026-10-30Form 4
James Healy, Director, Oct 28, 2026, about $20M. Bought 2 days before the company's next earnings release on 2026-10-30Form 4
, Director, Oct 23, 2026, about $98K. Bought 7 days before the company's next earnings release on 2026-10-30
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies
